AbbVie raises annual profit forecast as Humira stays strong, new drugs impress
AbbVie on Thursday raised its annual profit forecast after beating analysts' estimates for second-quarter earnings on a lower-than-expected fall in sales of blockbuster arthritis drug Humira and strong sales of newer treatments.